| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
22043 |
| Drug |
Polatuzumab vedotin |
| Brand |
Polivy® |
| Indication |
In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). |
| Rapid review commissioned |
27/06/2022 |
| Rapid review completed |
27/07/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pola-R-CHP compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/08/2022 |
| Pre-submission consultation with Applicant |
08/11/2022 |
| Full submission received from Applicant |
26/01/2023 |
| Preliminary review sent to Applicant |
20/07/2023 |
